Retraction notice for Long-term outcomes of 530 esophageal squamous cell carcinoma patients with minimally invasive Ivor Lewis esophagectomy. J Surg Oncol. 2018; 117:957-969.

Long-term outcomes of 530 esophageal squamous cell carcinoma patients with minimally invasive Ivor Lewis esophagectomy. J Surg Oncol. 2018; 117:957-969. https://doi.org/10.1002/jso.24997 The above article, published online on May 30, 2018 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the authors and the Journal Editor in Chief Dr. Stephen Sener and Wiley Periodicals, Inc. The retraction has been agreed following concerns raised that the number of patients operated on was considerably lower than the number of patients reported in the article. When asked to provide documentary evidence of the operations performed, the authors confirmed the reported discrepancy and requested to retract their article.

Long-term outcomes of 530 esophageal squamous cell carcinoma patients with minimally invasive Ivor Lewis esophagectomy.

BACKGROUND AND OBJECTIVES: The short-term benefits of minimally invasive esophagectomy (MIE) Ivor Lewis were proved, but 6-year outcomes in esophageal squamous cell carcinoma (ESCC) patients remain unclear. We sought to investigate perioperative outcomes, quality of life (QOL), survival and impact of adjuvant therapy in ESCC patients who underwent MIE Ivor Lewis. METHODS: We conducted a retrospective review of 530 ESCC patients treated with MIE Ivor Lewis from 2011 to 2016. Relevant variables were collected and assessed. Overall survival (OS) and disease-free survival (DFS) was analyzed by Kaplan-Meier or Cox proportional hazards modeling. RESULTS: Median operation duration was 266 min. The median number of lymph nodes was 28. The 30-day postoperative mortality was 1.7%. At a median follow-up of 41 months, the 6-year OS and DFS were 44.7% and 46.1%. Adjuvant chemoradiotherapy offered survival advantages in advanced stage patients. Pathological tumor-node-metastasis stage, postoperative complications, and recurrent laryngeal nerve lymphadenectomy were independent prognostic factors based on multivariate analysis. Generalized estimating equation analysis showed a rapid postoperative QOL improvement. CONCLUSIONS: MIE Ivor Lewis is a safe and feasible procedure in ESCC patients. It offers satisfactory perioperative outcomes, rapid QOL improvement, and acceptable long-term oncologic survival. Adjuvant chemoradiotherapy may improve OS and DFS in advanced stage patients.

Insights into the role of NAMPT and its inhibitors in the metabolism of tumor cells / 肿瘤

Different from normal cells, tumor cells display a metabolic profile by facilitate glycolysis pathway to provide adenosine triphosphate (ATP) quickly for cell growth and survival. Therefore, the demand of nicotinamide adenine dinucleotide (NAD), an important coenzyme in glycolysis pathway, increases obviously in tumor cells. It has been reported that tumor cells synthetize NAD through the primary salvage pathway, in which nicotinamide phosphoribosyltransferase (NAMPT) is the rate-limiting enzyme. As such, NAMPT regulates the cellular metabolism directly through controlling NAD synthesis and indirectly via affecting the activity of NAD-dependent enzymes. Meanwhile, NAMPT can ensure the viability of tumor cells by up-regulating the level of nicotinamide adenine dinucleotide phosphate (NADPH). Recently, NAMPT has been proposed as a new potential target for cancer treatment, and a number of studies have implicated that the NAMPT inhibitor has obvious anti-cancer effects. This review summarizes the alternation of metabolism in tumor cells, highlights the crucial role of NAMPT in cellular metabolism, and discusses the anticancer effect and the potential clinical application of NAMPT inhibitors in cancer treatment.